StocksFundsScreenerSectorsWatchlists
APLS

APLS - Apellis Pharmaceuticals Inc Stock Price, Fair Value and News

51.48USD-0.31 (-0.60%)Market Closed

Market Summary

APLS
USD51.48-0.31
Market Closed
-0.60%

APLS Alerts

  • 5 major insider sales recently.

APLS Stock Price

View Fullscreen

APLS RSI Chart

APLS Valuation

Market Cap

6.2B

Price/Earnings (Trailing)

-11.74

Price/Sales (Trailing)

15.65

EV/EBITDA

-11.41

Price/Free Cashflow

-10.42

APLS Price/Sales (Trailing)

APLS Profitability

EBT Margin

-132.76%

Return on Equity

-271.76%

Return on Assets

-67.02%

Free Cashflow Yield

-9.59%

APLS Fundamentals

APLS Revenue

Revenue (TTM)

396.6M

Rev. Growth (Yr)

545.89%

Rev. Growth (Qtr)

32.59%

APLS Earnings

Earnings (TTM)

-528.6M

Earnings Growth (Yr)

46.64%

Earnings Growth (Qtr)

36.84%

Breaking Down APLS Revenue

Last 7 days

-4.3%

Last 30 days

-9.3%

Last 90 days

-22.3%

Trailing 12 Months

-36.4%

How does APLS drawdown profile look like?

APLS Financial Health

Current Ratio

3.1

Debt/Equity

0.48

Debt/Cashflow

-6.39

APLS Investor Care

Shares Dilution (1Y)

8.35%

Diluted EPS (TTM)

-4.46

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023105.9M184.5M272.9M396.6M
202280.9M96.6M113.0M75.4M
2021204.6M158.6M112.6M66.6M
20206.5M6.1M128.4M250.6M
20193.5M4.0M4.6M5.1M
20181.6M003.0M
2017000277.8K

Tracking the Latest Insider Buys and Sells of Apellis Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 12, 2024
dunlop a. sinclair
acquired
19,785
13.19
1,500
-
Apr 08, 2024
deschatelets pascal
sold
-3,743,610
54.1711
-69,107
chief scientific officer
Apr 08, 2024
deschatelets pascal
acquired
259,842
3.76
69,107
chief scientific officer
Apr 01, 2024
sullivan timothy eugene
acquired
40,120
10.03
4,000
chief financial officer
Apr 01, 2024
sullivan timothy eugene
sold
-234,640
58.66
-4,000
chief financial officer
Mar 19, 2024
dunlop a. sinclair
sold
-1,068,160
57.179
-18,681
-
Mar 18, 2024
delong mark jeffrey
sold
-564,050
56.9
-9,913
chief business & strat officer
Mar 15, 2024
chopas james george
sold
-10,388
56.461
-184
vp/chief accounting officer
Mar 13, 2024
nicholson nur
sold
-645,838
57.5613
-11,220
chief technical officer
Mar 08, 2024
deschatelets pascal
sold
-4,297,550
62.1869
-69,107
chief scientific officer

1–10 of 50

Which funds bought or sold APLS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 12, 2024
AdvisorNet Financial, Inc
reduced
-8.00
-1,446
13,519
-%
Apr 12, 2024
DNB Asset Management AS
new
-
356,556
356,556
-%
Apr 11, 2024
Fortitude Family Office, LLC
unchanged
-
-6.00
353
-%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
unchanged
-
-36.00
1,999
-%
Apr 05, 2024
CWM, LLC
added
403
49,000
61,000
-%
Apr 05, 2024
GAMMA Investing LLC
added
103
6,477
13,755
-%
Mar 27, 2024
NOMURA HOLDINGS INC
new
-
879,643
879,643
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
added
0.04
2,615,420
7,170,330
0.01%
Mar 11, 2024
VANGUARD GROUP INC
added
0.9
211,765,000
572,003,000
0.01%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
87.21
24,561,600
37,183,000
-%

1–10 of 37

Are Funds Buying or Selling APLS?

Are funds buying APLS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own APLS
No. of Funds

Unveiling Apellis Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
t. rowe price investment management, inc.
5.3%
6,303,584
SC 13G
Feb 14, 2024
ecor1 capital, llc
9.4%
11,173,068
SC 13G/A
Feb 14, 2024
avoro capital advisors llc
9.9%
13,411,111
SC 13G/A
Feb 13, 2024
vanguard group inc
8.06%
9,555,678
SC 13G/A
Feb 08, 2024
wellington management group llp
13.91%
16,477,850
SC 13G/A
Sep 08, 2023
wellington management group llp
12.55%
14,770,859
SC 13G/A
Jul 18, 2023
ecor1 capital, llc
5.4%
6,307,547
SC 13G
Jul 07, 2023
blackrock inc.
4.9%
5,747,184
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
5.3%
5,842,660
SC 13G
Feb 14, 2023
avoro capital advisors llc
9.6%
10,625,000
SC 13G/A

Recent SEC filings of Apellis Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Apr 15, 2024
4
Insider Trading
Apr 09, 2024
4
Insider Trading
Apr 08, 2024
144
Notice of Insider Sale Intent
Apr 02, 2024
4
Insider Trading
Apr 01, 2024
144
Notice of Insider Sale Intent
Mar 20, 2024
4
Insider Trading
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
144
Notice of Insider Sale Intent
Mar 18, 2024
144
Notice of Insider Sale Intent
Mar 18, 2024
4
Insider Trading

Peers (Alternatives to Apellis Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
39.7B
6.8B
0.01% -33.89%
-8.42
5.79
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.6B
1.8B
-1.06% -27.57%
-42.25
10.17
76.23% 61.08%
17.3B
2.4B
9.12% -7.56%
103
7.14
15.42% 18.43%
12.0B
3.7B
-8.48% -28.30%
20.07
3.25
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.27% -36.41%
-11.74
15.65
425.83% 18.94%
4.5B
-
-6.46% 74.90%
-6.94
60.35
54.84% -34.79%
3.2B
270.6M
-9.62% -0.34%
-13.52
11.95
440.80% -27.84%
3.0B
240.7M
-15.06% -21.14%
-10.03
12.36
-1.03% -92.09%
2.8B
726.4M
-8.60% -6.11%
-45.41
3.83
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-4.17% -12.95%
25.42
4.56
85.90% -14.05%
576.6M
983.7M
-22.12% -55.02%
-1.06
0.59
-50.36% 17.16%
448.6M
881.7K
-2.13% 345.78%
-10.06
466.16
-77.61% -5.33%
256.8M
4.9M
2.33% 7.75%
-1.9
52.78
-54.97% 51.72%
6.7M
2.1M
82.86% 81.13%
-0.25
2.14
-13.45% 66.37%

Apellis Pharmaceuticals Inc News

Latest updates
MarketBeat17 hours ago

Apellis Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue32.6%146,377,000110,399,00094,969,00044,846,00022,663,00022,056,00016,322,00014,381,00060,290,0005,650,000623,000723,500824,000924,5001,025,0002,275,0001,478,7791,342,0001,421,000867,000633,701
Operating Expenses-6.7%230,894,500247,479,000215,410,000219,929,000186,716,000174,994,000164,946,000143,379,000149,694,000133,645,000194,910,000124,591,000119,879,000130,198,000115,508,000--69,948,000---
  S&GA Expenses-2.7%141,701,000145,648,000111,373,000102,093,00084,367,50078,406,00063,203,00051,187,00041,462,00045,763,00048,967,00040,579,00044,492,00036,991,00028,414,00029,504,00027,468,00018,629,00012,778,0008,171,0006,390,797
  R&D Expenses-12.8%69,281,50079,421,00095,658,000110,027,00099,423,00095,207,000101,661,00090,945,00078,181,00087,733,00095,943,00084,012,00050,337,50093,207,00087,094,00069,282,00078,472,00051,319,00050,698,00040,480,00030,806,035
EBITDA Margin40.4%-1.31-2.21-3.54-6.48-8.55-5.53-6.50-8.55-11.03-2.94-2.05-1.59---------
Interest Expenses-100.0%-1,643,000-1,643,000-1,643,000-3,360,000-3,372,000-6,893,000-9,100,000-3,829,00028,000231,000140,000588,000477,306
Income Taxes506.9%1,414,000233,000194,000300,000-1,471,000446,000486,0001,208,000352,000------------
Earnings Before Taxes37.7%-87,153,000-140,004,000-121,843,000-177,496,000-167,462,000-190,823,000-155,491,000-137,727,000-147,581,000-195,571,000-219,191,000-183,659,000---------
EBT Margin40.3%-1.33-2.22-3.56-6.53-8.64-5.59-6.58-8.65-11.21-3.05-2.16-1.68---------
Net Income36.8%-88,576,000-140,237,000-122,037,000-177,778,000-165,991,000-191,269,000-155,977,000-138,935,000-147,933,000-195,571,000-219,191,000-183,659,00078,265,000-135,700,000-118,617,000-168,822,000-113,218,000-69,825,000-71,090,000-50,574,000-36,459,475
Net Income Margin40.0%-1.33-2.22-3.56-6.53-8.65-5.61-6.61-8.67-11.21-4.62-2.90-1.76---------
Free Cashflow42.1%-97,970,000-169,132,000-150,527,000-177,879,000-141,595,000-154,613,000-107,415,000-111,646,000-112,518,000-168,977,000-128,936,000-153,798,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-3.6%7898189169797608731,0021,146882526700810961768870689389466317318204
  Current Assets-3.8%7667978939547208329601,104824475655774917742854672373451308311202
    Cash Equivalents-22.4%351452616765552584604633640284271265567416317418352434289288176
  Inventory48.5%14699.0010385.0086.0060.0048.0033.0016.002.004.00----------
  Net PPE-9.3%4.005.005.006.006.006.006.006.006.007.007.007.007.007.002.002.002.002.001.001.001.00
Liabilities1.4%59458657056759056566868468358384175875666263843035532715894.0043.00
  Current Liabilities33.4%24818617513916811512712513294.0015884.0012875.0058.0051.0066.0045.0036.0020.0017.00
  Long Term Debt0.1%93.0093.0093.0093.0093.0093.00189189189190386386359354349145143----
    LT Debt, Non Current0.1%93.0093.0093.0093.0093.0093.00189189189190386386359354349145143----
Shareholder's Equity-16.3%195232345412170307334462199--52.0020510623225934.00140159225161
  Retained Earnings-3.2%-2,837-2,748-2,600-2,486-2,308-2,142-1,951-1,795-1,656-1,508-1,313-1,093-926-1,004-868-750-581-468-398-327-276
  Additional Paid-In Capital1.8%3,0362,9822,9552,9002,4802,4532,2892,2601,8571,4531,1741,1471,1311,1121,1011,008616608558552438
Shares Outstanding1.0%12011811811611111010710684.0087.0081.0079.00---------
Float---10,700---4,800---4,074---1,954---1,151--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations42.1%-97,875-169,085-150,155-177,620-140,744-154,417-107,024-111,560-112,499-168,625-128,688-153,314141,979-99,824-94,294-108,349-82,071-53,597-39,907-35,560-44,478
  Share Based Compensation21.2%26,21921,62529,27828,82324,24123,54122,53020,77319,31217,19417,72216,43912,49412,09911,4899,2947,1075,2954,1834,5591,828
Cashflow From Investing108.5%4.00-47.00-372-259124,129124,78482,929-271,94984,980179,649129,752-146,765-91.00198,763-287,807-227,854-155-471-192-875-
Cashflow From Financing-168.1%-3,9135,7461,560391,106-15,9469,636-4,735376,704383,9582,1204,5261,6326,317926281,668403,267209198,95040,964148,418115

APLS Income Statement

2023-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue:   
Total product revenue, net$ 396,591$ 75,422$ 66,563
Operating expenses:   
Cost of sales58,5105,636200
Research and development354,387387,236345,869
Cost of research collaboration  75,000
License expense  5,000
General and administrative500,815277,163176,771
Total operating expenses:913,712670,035602,840
Net operating loss(517,121)(594,613)(536,277)
Loss on conversion of debt (32,890)(100,589)
Loss from remeasurement of development derivative liability  (97,675)
Interest income20,9338,914418
Interest expense(29,581)(32,626)(13,241)
Other(expense)/ income, net(727)(288)1,362
Net loss before taxes(526,496)(651,503)(746,002)
Income tax expense2,132669352
Net loss(528,628)(652,172)(746,354)
Other comprehensive income/(loss):   
Unrealized (loss)/gain on marketable securities (1)9
Unrealized (loss)/gain on pension plans(2,618)1,646 
Foreign currency (loss)(49)(430)(1,982)
Total other comprehensive income/(loss)(2,667)1,215(1,973)
Comprehensive loss, net of tax$ (531,295)$ (650,957)$ (748,327)
Net loss per common share, basic$ (4.45)$ (6.15)$ (8.84)
Net loss per common share, diluted$ (4.45)$ (6.15)$ (8.84)
Weighted-average number of common shares used in net loss per common share, basic118,678106,11484,421
Weighted-average number of common shares used in net loss per common share, diluted118,678106,11484,421
Product revenue, net [Member]   
Revenue:   
Total product revenue, net$ 366,281$ 65,092$ 15,147
Licensing and other revenue [Member]   
Revenue:   
Total product revenue, net$ 30,310$ 10,330$ 51,416

APLS Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 351,185$ 551,801
Accounts receivable206,4427,727
Inventory146,36285,714
Prepaid assets38,82036,350
Restricted cash1,1141,273
Other current assets22,40836,658
Total current assets766,331719,523
Non-current assets:  
Right-of-use assets16,74518,747
Property and equipment, net4,3456,148
Other assets1,30915,799
Total assets788,730760,217
Current liabilities:  
Accounts payable37,51637,342
Accrued expenses127,80695,139
Current portion of development liability75,83029,504
Current portion of right-of-use liabilities6,4415,625
Total current liabilities247,593167,610
Long-term liabilities:  
Long-term development liability239,817315,647
Convertible senior notes93,03392,736
Right-of-use liabilities11,45414,352
Other liabilities2,312 
Total liabilities594,209590,345
Stockholders’ equity:  
Preferred stock, $0.0001 par value; 10,000 shares authorized and zero shares issued and outstanding at December 31, 2023 and 202200
Common stock, $0.0001 par value; 200,000 shares authorized at December 31, 2023 and 2022; 119,556 and 110,772 shares issued and outstanding at December 31, 2023 and 2022, respectively1211
Additional paid-in capital3,035,5392,479,596
Accumulated other comprehensive loss(3,542)(875)
Accumulated deficit(2,837,488)(2,308,860)
Total stockholders’ equity194,521169,872
Total liabilities and stockholders’ equity$ 788,730$ 760,217
APLS
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
 CEO
 WEBSITEapellis.com
 INDUSTRYBiotechnology
 EMPLOYEES767

Apellis Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Apellis Pharmaceuticals Inc? What does APLS stand for in stocks?

APLS is the stock ticker symbol of Apellis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Apellis Pharmaceuticals Inc (APLS)?

As of Mon Apr 15 2024, market cap of Apellis Pharmaceuticals Inc is 6.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of APLS stock?

You can check APLS's fair value in chart for subscribers.

What is the fair value of APLS stock?

You can check APLS's fair value in chart for subscribers. The fair value of Apellis Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Apellis Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for APLS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Apellis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether APLS is over valued or under valued. Whether Apellis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Apellis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for APLS.

What is Apellis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, APLS's PE ratio (Price to Earnings) is -11.74 and Price to Sales (PS) ratio is 15.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. APLS PE ratio will change depending on the future growth rate expectations of investors.